Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
Recruiting · NCT06742515 · Registry updated 2024-12-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm, precursor B-cell acute lymphoblastic leukemia | Recruiting | Phase 2 | 2024-12-19 | NCT06742515 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| First Affiliated Hospital of Zhejiang University | 201 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003 | Hangzhou | China | 1 |